Trials
10 active
12 in total · 10 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Pharmaceutical form:Concentrate for solution for infusion-Route of administration:IV infusion”In the company’s words, NCT07325292 on ClinicalTrials.gov
- Tested for
- Multiple Sclerosis (5 trials), Kidney Transplant Rejection, Systemic Lupus Erythematosus, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus
- Main trialPhase 3
- “The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: * This event-driven study will have variable duration depending on the recruitment rate, the event rate, the…”In the company’s words, NCT06141473 on ClinicalTrials.gov
- Other names
- SAR441344
Other drugs for Multiple Sclerosis
- IMU-838Immunic AG · Phase 3
- CT-P53Celltrion · Phase 3
- ABP 692Amgen · Phase 3
- Peginterferon beta-1aBiogen · Phase 3
- PrivosegtorOculis · Phase 3
- BCD-281Biocad · Phase 3
Coming up7
- 23 DecPhase 2 trial completes · ClinicalTrials.gov
- 28 Apr 2027Phase 2 trial completes · ClinicalTrials.gov
- 6 May 2027Phase 3 trial completes · ClinicalTrials.gov
- 15 Jul 2027Phase 3 trial completes · ClinicalTrials.gov
- 24 Mar 2028Phase 3 trial completes · ClinicalTrials.gov
- 15 Aug 2029Phase 2/3 trial completes · ClinicalTrials.gov
- 16 May 2031Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 12 NovNew trial: none to Phase 3 · ClinicalTrials.gov NCT07930624
Trials12
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 6 May 2027 | Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | |
| Phase 3Recruiting | 15 Jul 2027 | Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | |
| Phase 3Active, not recruiting | 24 Mar 2028 | Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis | |
| Phase 3Not yet recruiting | 16 May 2031 | A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants With Multiple Sclerosis | |
| Phase 2/3Recruiting | 15 Aug 2029 | A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation | |
| Phase 2Active, not recruiting | 21 Sep 2022 | Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis | |
| Phase 2Active, not recruiting | 4 Sep 2026 | Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus | |
| Phase 2Recruiting | 23 Dec 2026 | A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease | |
| Phase 2Active, not recruiting | 28 Apr 2027 | Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS) | |
| Phase 2Completed | 8 Nov 2023 | Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS) | |
| Phase 1Completed | 10 Apr 2020 | Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects | |
| Phase 3Authorised | not given | Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026